Oral candidiasis
Also known as: oral thrush · thrush
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Infectious Diseases Society of America (IDSA) · 2016 · 2016 update
The IDSA candidiasis guideline covers invasive and mucosal Candida infections, with a dedicated section on oropharyngeal candidiasis. That section separates mild disease from moderate-to-severe disease, and addresses fluconazole-refractory infection and chronic suppressive therapy. It is the main US reference for antifungal management of oral candidiasis, published in Clinical Infectious Diseases.
- A dedicated section addresses oropharyngeal candidiasis, split by disease severity and including refractory and suppressive-therapy scenarios. source
- The document updates the previous iteration of the IDSA candidiasis guidelines following new diagnostic, preventive and treatment data. source
- Mucosal candidiasis is included alongside invasive disease even though it is not classically invasive. source
No CED/EFP guideline indexed for this condition yet.
Every entry is added by hand and cited to the issuing society, so a gap here means we have not verified one — not that none exists. Know the right one? Tell us.
US vs EU key differences
No curated US/EU comparison yet for this disease.
What changed recently
- US2009 → 2016 update2016-02-15
The 2016 IDSA update revised the 2009 guideline by promoting echinocandins to preferred initial therapy for candidaemia in non-neutropenic patients, with fluconazole demoted to an alternative for selected, less critically ill patients because of azole resistance. Oropharyngeal candidiasis retained topical agents or oral fluconazole as first line, while echinocandins were positioned as intravenous options for oesophageal disease when oral therapy is not possible.
See the full update feed for changes across every system.